Feb 03
FeNO Testing in Asthma Management

The Role of FeNO Testing in Asthma Management

Asthma is a chronic lung condition that causes airway inflammation and affects approximately 262 million people worldwide1. Typical symptoms include: Wheezing, Breathlessness, Chest tightness, Coughing. When airways are inflamed, breathing can become difficult. Recent Asthma + Lung UK research found that over 42,000 people ended up in emergency care in... read more →
Jan 21
Jan 13

coVita™ and Allergy Partners team up to improve asthma care in America

Innovative NObreath® FeNO device is the allergists' device of choice in the USA. coVita™ LLC, a leader in advanced breath analysis and diagnostic solutions, serves as the U.S. distributor for the innovative NObreath® Fractional Exhaled Nitric Oxide (FeNO) device from UK-based Bedfont® Scientific Ltd. The new agreement with Allergy Partners... read more →
Jan 06
Nov 27

Bedfont® Scientific Limited Expands Global Access to FeNO Testing in India

Rbeck Healthtech Private completes registration for the NObreath® FeNO device, helping to improve asthma care across the region. Bedfont® Scientific Limited, world leaders in breath analysis, with over 48 years of experience in designing and manufacturing medical breath analysis devices, has collaborated with Rbeck Healtech Private to make Fractional exhaled... read more →
Nov 27
Nov 20
Nov 13
Nov 06
Oct 31
preparing asthma patients with FeNO monitoring

Winter is coming: preparing asthma patients with FeNO monitoring

Research has shown that seven out of ten people with asthma report that cold air exacerbates their asthma symptoms1. As winter approaches quickly, it is essential to prepare for asthma management in advance. A vital tool in asthma management, as recommended by the National Institute for Health and Care Excellence... read more →